Dr. Steven E. Come
Overview
Steven Come is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Come is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast.
His clinical research consists of co-authoring 77 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- MEDICARE-MEDICAID PLAN
- HMO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
330 Brookline Avenue, Shapiro 9, Boston, MA 02215
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Dana-Farber Cancer Institute, Breast Oncology Program
Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, DC. She was faculty at MedStar Georgetown University Hospital from 2015 to 2020 where she served as the institutional PI for Alliance and the co-PI for the National Capital Area (NCA) Minority/Underserved NCORP. In 2020, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers and novel therapies in the treatment of breast cancer. Dr. Lynce is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.
Beth Overmoyer is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Overmoyer is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.
Dana-Farber Cancer Institute, Breast Oncology Program
Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer. She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials. Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Breast CancerDr. Come isElite. Learn about Breast Cancer.
- Distinguished
- AngiosarcomaDr. Come isDistinguished. Learn about Angiosarcoma.
- Inflammatory Breast CancerDr. Come isDistinguished. Learn about Inflammatory Breast Cancer.
- Paget Disease of the BreastDr. Come isDistinguished. Learn about Paget Disease of the Breast.
- Experienced
- Breast Cancer in MenDr. Come isExperienced. Learn about Breast Cancer in Men.
- HER-2 Positive Breast CancerDr. Come isExperienced. Learn about HER-2 Positive Breast Cancer.